Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenofibrate for Prevention of Diabetic Retinopathy Worsening
NCT04661358Phase 3Active, not recruiting
- Sponsor
- Jaeb Center for Health Research
- Start
- Mar 2021
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in diabetic retinopathy (DR) comparing Fenofibrate 160-mg with Placebo (2 arms). Primary endpoint: Worsening of diabetic retinopathy at 6 years. Started Mar 2021; status: active, not recruiting.
02
Drugs
fenofibrate
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT04661358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661358.